ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA)
· seekingalpha.com
ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Read more on what could be next for this biotech.
About the TPT service
Thanks for reading. At the Total Pharma Tracker, we offer most of the following:-
For investors requiring hands-on support, our in-hou...